Skip to main content
LYSOGENE logo

LYSOGENE — Investor Relations & Filings

Ticker · LYS ISIN · FR0013233475 LEI · 969500T64RILK1RD0852 PA Professional, scientific and technical activities
Open in API
Filings indexed 254 across all filing types
Latest filing 2019-09-26 Board/Management Inform…
Country FR France
Listing PA LYS

About LYSOGENE

https://www.lysogene.com

Lysogene was a clinical-stage biotechnology company that specialized in the research and development of gene therapies for rare, inherited neurodegenerative diseases affecting the central nervous system (CNS). The company's approach focused on delivering a functional copy of a deficient gene directly to the brain to address the root cause of the targeted disorder. Its pipeline included investigational treatments for lysosomal storage diseases such as Sanfilippo syndrome type A (MPS IIIA) and GM1 gangliosidosis. Following clinical and financial challenges, the company initiated judicial liquidation proceedings in 2023.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Board/Management Information Classification · 1% confidence The document is a press release dated September 26, 2019, announcing the appointment of Carole Deffez as a new independent member of the Board of Directors ('nouvelle administratrice indépendante'). This action directly relates to changes in the company's governing body structure. According to the definitions, announcements of changes in the company's board of directors or senior management fall under the 'Board/Management Information' category, which corresponds to the code MANG.
2019-09-26 French
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Earnings Release Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and is dated September 5, 2019. It details significant clinical trial advancements (Phase 2-3 study progress, completion of a natural history study, launch of a new measurement study) and provides a summary of the company's first half of 2019 performance related to its MPS IIIA program. This format, focusing on key operational and clinical milestones rather than comprehensive financial statements (like a 10-K or IR), strongly suggests an Earnings Release (ER) or a general operational update. Since it focuses on clinical progress and operational highlights rather than comprehensive financial results for a specific reporting period (though it mentions 'premier semestre 2019'), it aligns best with the 'Earnings Release' category, which covers initial announcements of periodical results/highlights. It is not a full financial report (10-K or IR), nor is it a transcript (CT) or a presentation (IP). Given the context of reporting on the 'first half of 2019' progress, ER is the most appropriate fit among the provided options for a high-level operational/clinical update announcement. H1 2019
2019-09-05 French
Inside Information / Operations of the issuer (acquisitions, sales...)
Earnings Release Classification · 1% confidence The document is explicitly titled "Press Release" and dated September 5, 2019. It announces major advancements in the company's clinical program (MPS IIIA Phase 2-3 trial) and provides key operational updates (enrollment momentum, completion of natural history study, launch of PROVide study). This format, focusing on recent operational and clinical milestones rather than comprehensive annual financials (10-K) or detailed quarterly results (IR), strongly suggests an Earnings Release (ER) or a general announcement. Since it focuses on clinical trial progress and operational updates rather than just the summary financial figures typically associated with an ER, and given the context of a biopharma company, it functions as a significant operational update. However, the structure is that of a formal announcement intended for immediate public dissemination, often accompanying or preceding a more detailed report. Given the options, this is best classified as an Earnings Release (ER) as it reports on the status of the business during a period (First half 2019 developments) and is a standard format for communicating business performance updates, even if the focus is clinical rather than purely financial metrics. It is not a full report (IR/10-K) nor a simple announcement of a report (RPA). FY 2019
2019-09-05 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and explicitly announces the "Information financière du 2 ème trimestre 2019" (Financial information for the 2nd quarter of 2019), detailing cash position and revenue as of June 30, 2019. This content—a brief announcement of key financial highlights for a specific period (Q2 2019)—perfectly matches the definition of an Earnings Release (ER). It is not a comprehensive report (like 10-K or IR) nor a transcript (CT). Given its nature as an initial financial results announcement, ER is the most appropriate classification. H1 2019
2019-07-25 French
Inside Information / News release on accounts, results
Earnings Release Classification · 1% confidence The document is explicitly titled "Press Release" and its main heading is "LYSOGENE reports second quarter 2019 financial information". It provides key financial highlights for the period ending June 30, 2019 (Q2 2019), such as cash position (€33.2 million) and revenues (€7 million). This content structure—a brief announcement of period-end financial results—perfectly matches the definition of an Earnings Release (ER), which focuses on initial key highlights rather than the comprehensive details found in an Interim Report (IR) or Annual Report (10-K). The document length (2069 chars) is short, but it contains the core results, making ER the most appropriate classification over RPA. H1 2019
2019-07-25 English
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Board/Management Information Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and dated July 18, 2019. The content announces the creation of a Scientific Advisory Board (SAB) composed of international experts in gene therapy. This type of announcement, detailing strategic organizational developments, expert appointments, and pipeline updates, is characteristic of general corporate news releases aimed at investors and the public. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a press release announcing strategic organizational news (creation of an advisory board), it fits best under the general category for corporate announcements that don't fit a more specific financial or regulatory filing type. Given the options, this is a general corporate announcement. While 'RNS' (Regulatory Filings) is a fallback, the content is highly specific to management/strategic updates. However, since there is no specific code for 'Press Release' or 'Strategic Announcement' outside of the defined list, and this is not a management change (MANG) but an advisory board formation, it falls into the general regulatory/announcement category. Given the context of financial reporting databases, press releases announcing strategic appointments often fall under general regulatory announcements or are sometimes grouped with management/governance updates. Since the focus is on scientific expertise supporting development, and it's a press release, 'RNS' (Regulatory Filings/General Announcement) is the most appropriate general category if a more specific one like MANG (which usually implies director/executive changes) doesn't fit perfectly. However, the formation of an advisory board is a significant management/governance decision. Let's re-evaluate: MANG is for 'Board of Directors or senior management' changes. An SAB is advisory, not governing, but it is a high-level strategic/management addition. Given the options, and since it's a press release announcing a strategic addition, RNS is the safest general classification for non-standard announcements. If we strictly interpret the definitions, it's an announcement of strategic organizational structure, which is closest to MANG or RNS. I will classify it as RNS as it is a general press release announcing a strategic development rather than a change in the formal Board of Directors.
2019-07-18 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.